AVXL Faces Investor Scrutiny as Shareholder Rights Law Firm Launches Fraud Investigation
Market Chameleon (Thu, 4-Dec 11:22 AM)
AVXL Navigates Regulatory Hurdles with Blarcamesine for Early Alzheimer’s Disease—What’s Next for Investors?
Market Chameleon (Mon, 17-Nov 11:53 AM)
Regulatory Path Forward for Anavex: EMA Requests Re-Examination on Blarcamesine for Early Alzheimer's
Market Chameleon (Fri, 14-Nov 7:33 AM)
